Lucius Lorlatinib – Buy Online
Lucius Lorlatinib – Buy Online
Lucius Lorlatinib – Buy Online
Lucius Lorlatinib – Buy Online

Lucius Lorlatinib – Buy Online

Price range: EUR 74.67 through EUR 233.33

500+ vendidos
Preco promocional

Farmacia fisica em Hong Kong, 100% de autenticidade garantida

Destaques do produto

Lorlatinib is a third-generation small-molecule ALK/ROS1 dual inhibitor approved by the FDA in November 2018. It is a prescription medicine and should be used only under medical guidance.

Garantias de servico

Envio direto internacionalFarmacia autorizadaRevisado por farmaceuticoGarantia de autenticidade

Especificacoes

Especificacao
25mg*30 100mg*30
Fabricante
Lucius Pharmaceuticals
Envio
Hong Kong
SKU: n.d. Categoria: Etiquetas: , , , Marca:

Informacoes do produto

Nome em ingles
Lorlatinib
Nome generico
Lorlatinib

Especificacoes

Especificacao
25mg*30 100mg*30
Fabricante
Lucius Pharmaceuticals
Envio
Hong Kong

Detalhes completos

Indicacoes

Indicated for adults with ALK-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

Mecanismo de acao

， ALK ROS1 TYK1 FER FPS TRKA TRKB TRKC FAK FAK2 ACK ALK ， ALK EML4 ALK 1 ALK ALK G1202R I1171T ， ，

Farmacologia

12.1 Como funciona ， ALK ROS1 TYK1 FER FPS TRKA TRKB TRKC FAK FAK2 ACK ALK ， ALK EML4 ALK 1 ALK ALK G1202R I1171T ， ，

Dosagem

2.1 ALK LORBRENA NSCLC [ (1) (14)] FDA NSCLC ALK ， LORBRENA 100 mg， ， [ (12.3)] ，

Precaucoes

5.1 CYP3A 12 10 ​​ LORBRENA ， CYP3A ， 50% 4 (ALT) (AST) ，33% 3 ALT AST ，8% 2 ALT AST ALT AST 3 ， 15 7 34 3 4 ALT AST 18 ，2 ALT AST 7 [ (7.1)] CYP3A LORBRENA CYP3A CYP3A 3

Contraindicacoes

，LORBRENA CYP3A [ Precaucoes 5.1 ]

Interacoes medicamentosas

7.1 CYP3A CYP3A [ (4)] ， CYP3A ， 3 [ Dosagem (2.3)] CYP3A [ (12.3)]， CYP3A

Reacoes adversas

Descrição • CYP3A [ Precaucoes (5.1)]• [ Precaucoes (5.2)]• [ Precaucoes (5.3)]• [ Precaucoes (5.4)]• / [ Precaucoes (5.5)]• [ Precaucoes (5.6)]• [ Precaucoes (5.7)] 6.1 ，

Armazenamento

11 LORBRENA 11 LORBRENA (mg) NDC 25 30 ， 0069-0227-01 8 ， ， ， “Pfizer”， “25” “LLN” 25 120 ， 0069-0227-03 8

Package Insert

Appearance

3 • 25 8 ， ， ， ， “Pfizer”， “25” “LLN” • 100 8.5 × 17 ， ， ， ， “Pfizer”， “LLN 100” 25 100 (3)

Indications

Indicated for adults with ALK-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

Dosagem

2.1 ALK LORBRENA NSCLC [ (1) (14)] FDA NSCLC ALK ， LORBRENA 100 mg， ， [ (12.3)] ，

Reacoes adversas

Descrição • CYP3A [ Precaucoes (5.1)]• [ Precaucoes (5.2)]• [ Precaucoes (5.3)]• [ Precaucoes (5.4)]• / [ Precaucoes (5.5)]• [ Precaucoes (5.6)]• [ Precaucoes (5.7)] 6.1 ，

Contraindicacoes

，LORBRENA CYP3A [ Precaucoes 5.1 ]

Precautions

5.1 CYP3A 12 10 ​​ LORBRENA ， CYP3A ， 50% 4 (ALT) (AST) ，33% 3 ALT AST ，8% 2 ALT AST ALT AST 3 ， 15 7 34 3 4 ALT AST 18 ，2 ALT AST 7 [ (7.1)] CYP3A LORBRENA CYP3A CYP3A 3

Use in Pregnancy and Lactation

8.1 Como funciona[ (12.1)]，LORBRENA LORBRENA ， ， ， AUC 100 mg ， ，

Interacoes medicamentosas

7.1 CYP3A CYP3A [ (4)] ， CYP3A ， 3 [ Dosagem (2.3)] CYP3A [ (12.3)]， CYP3A

Clinical Pharmacology

12 12.1 Como funciona ， ALK ROS1 TYK1 FER FPS TRKA TRKB TRKC FAK FAK2 ACK ALK ， ALK EML4 ALK 1 ALK ， ALK G1202R I1171T ， ， EML4-ALK

Clinical Studies

14 ALK CROWN B7461006 NCT03052608 LORBRENA ALK ECOG 0-2 ， VENTANA ALK (D5F3) CDx ALK ， ， ， 2 4 ，

Armazenamento

11 LORBRENA 11 LORBRENA (mg) NDC 25 30 ， 0069-0227-01 8 ， ， ， “Pfizer”， “25” “LLN” 25 120 ， 0069-0227-03 8

Avaliacoes do produto (11)

Filtro: Todas as avaliacoes
4.7★★★★★
11 avaliacoes de clientes9 compras verificadas
+o***e· ha 3 semanas
★★★★
+t***3· ha 1 meses
Compra verificada
★★★★★

Descricao

Indicacoes

Indicated for adults with ALK-positive non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

Mecanismo de acao

， ALK ROS1 TYK1 FER FPS TRKA TRKB TRKC FAK FAK2 ACK ALK ， ALK EML4 ALK 1 ALK ALK G1202R I1171T ， ，

Farmacologia

12.1 Como funciona ， ALK ROS1 TYK1 FER FPS TRKA TRKB TRKC FAK FAK2 ACK ALK ， ALK EML4 ALK 1 ALK ALK G1202R I1171T ， ，

Dosagem

2.1 ALK LORBRENA NSCLC [ (1) (14)] FDA NSCLC ALK ， LORBRENA 100 mg， ， [ (12.3)] ，

Precaucoes

5.1 CYP3A 12 10 ​​ LORBRENA ， CYP3A ， 50% 4 (ALT) (AST) ，33% 3 ALT AST ，8% 2 ALT AST ALT AST 3 ， 15 7 34 3 4 ALT AST 18 ，2 ALT AST 7 [ (7.1)] CYP3A LORBRENA CYP3A CYP3A 3

Contraindicacoes

，LORBRENA CYP3A [ Precaucoes 5.1 ]

Interacoes medicamentosas

7.1 CYP3A CYP3A [ (4)] ， CYP3A ， 3 [ Dosagem (2.3)] CYP3A [ (12.3)]， CYP3A

Reacoes adversas

Descrição • CYP3A [ Precaucoes (5.1)]• [ Precaucoes (5.2)]• [ Precaucoes (5.3)]• [ Precaucoes (5.4)]• / [ Precaucoes (5.5)]• [ Precaucoes (5.6)]• [ Precaucoes (5.7)] 6.1 ，

Armazenamento

11 LORBRENA 11 LORBRENA (mg) NDC 25 30 ， 0069-0227-01 8 ， ， ， “Pfizer”， “25” “LLN” 25 120 ， 0069-0227-03 8

Informacoes adicionais

Especificacao

25mg*30片, 100mg*30片